Sergio Cifuentes Canaval, Medical Oncologist at Las Américas Auna Clinic, shared a post on LinkedIn:
“Important news in ER+ advanced breast cancer.
Roche has announced positive results from the phase III evERA trial, evaluating giredestrant + everolimus versus fulvestrant + everolimus in patients with ER+, HER2- advanced breast cancer previously treated with CDK4/6 inhibitors.
- The trial met its primary endpoint: giredestrant + everolimus significantly improved progression-free survival (PFS) compared to the control arm.
- The safety profile was consistent and manageable, showing tolerability of the combination.
- These results highlight the potential of giredestrant, a next-generation oral SERD, in a population with unmet needs after progression on CDK4/6 inhibitors.”
More posts featuring Sergio Cifuentes Canaval on OncoDaily.